NCT03058406View on ClinicalTrials.gov

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

CompletedOBSERVATIONAL

Enrollment

256

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

November 4, 2018

Study Completion Date

November 4, 2018

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG

Eribulin mesylate

Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.

Trial Locations (2)

Unknown

Osaka

Tokyo

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT03058406 - A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter